Compare Payoneer Global Inc (PAYO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs Zoetis Inc — how do they compare? Payoneer Global Inc trades at $7.15 (market cap $2.43B), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 12.4× Payoneer Global Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 61 Days and Zoetis Inc for 70 Days on average.
| PAYO | ZTS | |
|---|---|---|
Market Cap | $2.43B | $30.20B |
Volume | 1,342,701 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $7.18 | $147.53 |
52-Week Low | $4.27 | $69.09 |
Typical Hold Time | 61 Days | 70 Days |
Enterprise Value | $2.17B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.14, down 0.28% on the day, with a bullish technical outlook supported by moving averages. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but maintains strong revenue growth and a 78% gross margin. Recent news highlights the renewal of its partnership with Etsy through 2029 and ongoing acquisition discussions with Nuvei.
The stock presents a mixed outlook: analyst consensus is 60% buy with no sell ratings, but elevated P/E of 51.18 and recent earnings misses pose valuation and execution risks. The pending acquisition adds uncertainty, while expansion into India offers growth potential. Investors should weigh strong fundamentals against high expectations and integration challenges.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
